List of projects qualified for funding in NCN call EXPRESS CALL TO FUND RESEARCH ON COVID-19

  • Coordinator: Dr inż. Tomasz Szumełda
  • Date of call announcement: 30th March, 2020

lp. Project title Principal Investigator Name of entity Requested funds (PLN) Granted funds (PLN) Panel
1. SARS-CoV-2 mRNA capping machinery – studies on nsp14 and nsp16 methyltransferase activity using high-throughput fluorescence method dr hab. Jacek Jemielity, prof. UW Uniwersytet Warszawski 769 200 769 200 ST4
2. Retargeting of known drugs towards proteases involved in the development of COVID-19 disease prof. dr hab. Marcin Drąg Politechnika Wrocławska 1 590 000 1 590 000 NZ1
3. Potential SARS-Cov-2 antiviral strategy based on the inhibition of programmed ribosomal frameshifting. prof. dr hab. Joanna  Kufel Uniwersytet Warszawski 877 920 877 920 NZ1
4. SARS-CoV-2 RNA, target for inhibition of virus replication prof. dr hab. Elżbieta Kierzek Instytut Chemii Bioorganicznej Polskiej Akademii Nauk 1 026 000 990 000 NZ6
5. Determination of the 3D structure of key regulatory regions at the 5' and 3' termini of SARS-CoV-2 RNA and identification of small molecule compounds that prevent the formation of these structures prof. dr hab. Janusz Bujnicki, czł. koresp. PAN Międzynarodowy Instytut Biologii Molekularnej i Komórkowej w Warszawie 999 000 951 000 NZ1
6. Peptide foldamer-based inhibitors of human ACE2 – SARS-CoV-2 S protein interaction dr hab. Łukasz Berlicki Politechnika Wrocławska 465 600 465 600 ST4
7. iCovid, impedimetric platform based on boron-doped diamond nanostructures for quantitative analysis of virus-receptor interactions dr hab. Robert Bogdanowicz, prof. PG Politechnika Gdańska 1 096 200 536 400 ST7
8. Involvement of cell-surface vimentin in SARS-CoV-2 cell entry prof. dr hab. Robert Bucki Uniwersytet Medyczny w Białymstoku 514 560 514 560 NZ6
9. The impact of the COVID-19 pandemic on engagement in solving collective problems dr Katarzyna Jaśko Uniwersytet Jagielloński 352 800 352 800 HS6
10. Ethics of clinical trials in COVID-19 pandemic dr hab. Marcin  Waligóra, prof. UJ Uniwersytet Jagielloński 244 800 244 800 HS1
11. Elucidation and treatment of a cytokine storm syndrome as an approach to combat fatal complications of COVID-19 prof. dr Marcin Mycko Uniwersytet Warmińsko-Mazurski w Olsztynie 1 080 000 1 080 000 NZ6
12. dr hab. Ewelina Król Uniwersytet Gdański 999 600 999 600 NZ6
13. Evaluation of the role of inflammasome in the pathogenesis of COVID-19- establishment of in vitro experimental platform. dr Tomasz Skirecki Centrum Medyczne Kształcenia Podyplomowego 406 800 406 800 NZ6
14. Validation of PDB models of potential drug design targets for SARS-CoV-2 coronavirus prof. dr hab. Mariusz Jaskólski Instytut Chemii Bioorganicznej Polskiej Akademii Nauk 384 000 384 000 NZ1
15. Rapid and operationally simple SARS-CoV-2 tests using CRISPR tools prof. dr hab. Matthias Bochtler Instytut Biochemii i Biofizyki Polskiej Akademii Nauk 243 085 243 085 NZ1
16. Health behavior change during COVID-19 pandemic: the focus on handwashing prof. dr hab. Aleksandra Łuszczyńska SWPS Uniwersytet Humanstycznospołeczny 297 840 297 840 HS6
17. SARS-CoV-2 papain-like protease: inhibition of a viral processing and deubiquitinating enzyme – comprehensive in silico approach dr hab. Joanna Sułkowska, prof. UW Uniwersytet Warszawski 135 240 135 240 NZ7
18. TMPRSS2 – a potential new drug target and a determinant of COVID19 outcome dr Paweł Zmora Instytut Chemii Bioorganicznej Polskiej Akademii Nauk 1 064 400 988 800 NZ6
19. Fear of a pandemic. Biases in risk perception and risk taking in the time of coronavirus dr hab. Michał Krawczyk, prof. UW Uniwersytet Warszawski 323 697 323 697 HS4

Statistics

Information on the proposals submitted and recommended for funding can be found below.

Panel Number of proposals
submitted under merit-based evaluation recommended for funding
HS 115 112 4
NZ 109 109 12
ST 38 38 3
Total 262 259 19

Follow-up

Please remember that the data presented is for information purposes only. The NCN Director will soon issue administrative decisions that will be then delivered to the applicants.